Takeda Korea's Kynteles SC wins insurance benefit

Korea Biomedical Review

1 December 2022 - Takeda Pharmaceuticals Korea said Kynteles SC, an inflammatory bowel disease treatment, started to be covered by health insurance on Thursday.

Kynteles SC is subcutaneously injectable at home with the same efficacy as Kynteles intravenous injection.

Read Korea Biomedical Review article

Michael Wonder

Posted by:

Michael Wonder